Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections – Pipeline Review, H1 2020, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.
Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 9, 17, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 8, 9, 1, 8 and 3 molecules, respectively.
Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections – Pipeline Review, H1 2020, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.
Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 9, 17, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 8, 9, 1, 8 and 3 molecules, respectively.
Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Cytomegalovirus (HHV-5) Infections - Overview
Cytomegalovirus (HHV-5) Infections - Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Drug Profiles
Cytomegalovirus (HHV-5) Infections - Dormant Projects
Cytomegalovirus (HHV-5) Infections - Discontinued Products
Cytomegalovirus (HHV-5) Infections - Product Development Milestones
Appendix
Cytomegalovirus (HHV-5) Infections - Overview
Cytomegalovirus (HHV-5) Infections - Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
Cytomegalovirus (HHV-5) Infections - Drug Profiles
Cytomegalovirus (HHV-5) Infections - Dormant Projects
Cytomegalovirus (HHV-5) Infections - Discontinued Products
Cytomegalovirus (HHV-5) Infections - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Abhelix LLC, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by AlloVir Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Artemis Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Children's National Research Institute, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Holdings Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by China Immunotech Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Evrys Bio, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Helocyte Biosciences Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Pharma Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Karyopharm Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Macrophage Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Nobelpharma Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Okogen Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Orgenesis Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Provention Bio Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by SL VaxiGen Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by SpyBiotech Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Stadius Biopharma LLC, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Synklino ApS, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Vichem Chemie Research Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Viramatix Sdn Bhd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..3), H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..4), H1 2020
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2020
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Abhelix LLC, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by AlloVir Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Artemis Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Children's National Research Institute, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Holdings Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by China Immunotech Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Evrys Bio, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Helocyte Biosciences Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Pharma Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Karyopharm Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Macrophage Therapeutics Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Nobelpharma Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Okogen Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Orgenesis Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Provention Bio Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by SL VaxiGen Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by SpyBiotech Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Stadius Biopharma LLC, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Synklino ApS, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Vichem Chemie Research Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Viramatix Sdn Bhd, H1 2020
Cytomegalovirus (HHV-5) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..3), H1 2020
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2020 (Contd..4), H1 2020
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Abhelix LLC
AIMM Therapeutics BV
AlloVir Inc
Artemis Therapeutics Inc
Atara Biotherapeutics Inc
Biotest AG
Chengdu Rongsheng Pharmaceutical Co Ltd
Children's National Research Institute
China Biologic Products Holdings Inc
China Immunotech Co Ltd
Evrys Bio
Fate Therapeutics Inc
GlaxoSmithKline Plc
Helocyte Biosciences Inc
Hookipa Pharma Inc
Kadmon Corp LLC
Karyopharm Therapeutics Inc
Macrophage Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Moderna Inc
Nobelpharma Co Ltd
Okogen Inc
Orgenesis Inc
Phoenix Biotechnology Inc
Provention Bio Inc
Qurient Co Ltd
Savoy Pharmaceuticals Inc
SL VaxiGen Inc
SpyBiotech Ltd
Stadius Biopharma LLC
Synklino ApS
Takeda Pharmaceutical Co Ltd
Themis Bioscience GmbH
Trellis Bioscience Inc
VBI Vaccines Inc
Vichem Chemie Research Ltd
Viramatix Sdn Bhd
Zhuhai Trinomab Biotechnology Co Ltd
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Abhelix LLC
AIMM Therapeutics BV
AlloVir Inc
Artemis Therapeutics Inc
Atara Biotherapeutics Inc
Biotest AG
Chengdu Rongsheng Pharmaceutical Co Ltd
Children's National Research Institute
China Biologic Products Holdings Inc
China Immunotech Co Ltd
Evrys Bio
Fate Therapeutics Inc
GlaxoSmithKline Plc
Helocyte Biosciences Inc
Hookipa Pharma Inc
Kadmon Corp LLC
Karyopharm Therapeutics Inc
Macrophage Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Moderna Inc
Nobelpharma Co Ltd
Okogen Inc
Orgenesis Inc
Phoenix Biotechnology Inc
Provention Bio Inc
Qurient Co Ltd
Savoy Pharmaceuticals Inc
SL VaxiGen Inc
SpyBiotech Ltd
Stadius Biopharma LLC
Synklino ApS
Takeda Pharmaceutical Co Ltd
Themis Bioscience GmbH
Trellis Bioscience Inc
VBI Vaccines Inc
Vichem Chemie Research Ltd
Viramatix Sdn Bhd
Zhuhai Trinomab Biotechnology Co Ltd
